Connect your AI

Viridian Therapeutics, Inc. VRDN Price / book

Price / book at other companies

AmgenAMGN

20.6×-6.3×

Immunovant, Inc.IMVT

5.9×+1.8×

ANI PharmaceuticalsANIP

3.1×-0.4×

Vir Biotechnology, Inc.VIR

1.8×+0.9×

Nektar TherapeuticsNKTR

3.6×-5.6×

Syndax PharmaceuticalsSNDX

49.5×+44.6×

Other financials

Income statement

Revenue$141.0K+95.8%

Operating income-$116.2M-23.8%

Net income-$104.9M-20.7%

EPS (diluted)-$1.15-5.5%

Balance sheet

Cash & equivalents$176.3M+51.7%

Total debt$36.8M+59.4%

Total equity$636.0M+5.2%

Total assets$789.0M+19.4%

Cash flow

Operating cash flow-$119.7M-29.1%

CapEx$23.0K-73.3%

Free cash flow-$119.7M-29.0%

Valuation

Market cap$1.91B+82.0%

Enterprise value$1.77B+85.0%

P/S26.9×-3,445×

Profitability

Gross margin36.3%—

Operating margin-543.9%-271pp

Net margin-508.5%-254pp

FCF margin-428.4%-214pp

Returns & leverage

Return on equity-58.1%+7.9pp

Debt / equity0.1×0.0×

Current ratio15.1×-4.3×

Where this comes from

Calculated from Viridian Therapeutics, Inc.’s reported figures.

market cap/total stockholders equity=3.1×

Based on the most recent quarter.

The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viridian Therapeutics, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Viridian Therapeutics, Inc.'s price / book?: Viridian Therapeutics, Inc. (VRDN) reported price / book of 3.1× in Q1 2026.
How has Viridian Therapeutics, Inc.'s price / book changed year-over-year?: Viridian Therapeutics, Inc.'s price / book increased by 73.0% year-over-year, from 1.8× to 3.1×.
What is the long-term trend for Viridian Therapeutics, Inc.'s price / book?: Over 5 years (2020 to 2025), Viridian Therapeutics, Inc.'s price / book has grown at a 36.5% compound annual growth rate (CAGR), from 0.9× to 4.1×.
What does price / book mean?: Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.